European Patent Office

Company

Related News

BioNxt Secures European Patent for Sublingual Cladribine Drug Delivery Technology

Feb 17, 2026

BioNxt Solutions Inc. receives European Patent No. 4539857 for its proprietary sublingual cladribine oral thin film drug delivery technology, providing protection across up to 39 European Patent Convention states through at least June 14, 2043.

FDA Accepts Savara's MOLBREEVI Application for Rare Lung Disease with August Decision Date

Feb 16, 2026

Savara Inc. announced the FDA has accepted its resubmitted Biologics License Application for MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis, with Priority Review granted and a target decision date of August 22, 2026.